Compare Stocks

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
AVEO AVEO Pharmaceuticals	$15.00	$14.97	$3.06 ▼ $15.00	$521.45M	1	601,442 shs	247,800 shs
ONCY Oncolytics Biotech	$1.03 -1.0%	$1.07	$0.88 ▼ $3.39	$77.68M	1.93	385,020 shs	158,995 shs
SAVA Cassava Sciences	$21.19 -0.4%	$21.91	$12.32 ▼ $32.10	$916.47M	-0.45	764,200 shs	966,540 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-88.78%
AVEO AVEO Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ONCY Oncolytics Biotech	-3.70%	-7.96%	0.00%	-11.11%	-9.57%
SAVA Cassava Sciences	+1.14%	-13.22%	-0.05%	-17.94%	+21.27%

Biden to Launch “FedNOW” [Move Your Money Now] (Ad)

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	0.9329 of 5 stars	3.5	3.0	0.0	0.0	1.3	0.0	0.0
SAVA Cassava Sciences	3.4757 of 5 stars	3.5	1.0	0.0	4.7	3.0	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	3.00	Buy	$4.00	288.35% Upside
SAVA Cassava Sciences	3.00	Buy	$124.00	485.18% Upside

Current Analyst Ratings

Latest AVEO, SAVA, ADMP, and ONCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2024	ONCY Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$3.00
3/5/2024	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$124.00
2/14/2024	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
1/19/2024	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
AVEO AVEO Pharmaceuticals	$42.29M	12.33	N/A	N/A	$1.33 per share	11.28
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.26 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
AVEO AVEO Pharmaceuticals	-$53.34M	-$0.84	N/A	28.85	N/A	-30.79%	-81.66%	-28.83%	N/A
ONCY Oncolytics Biotech	-$20.56M	-$0.30	N/A	N/A	N/A	N/A	-105.97%	-72.80%	5/3/2024 (Estimated)
SAVA Cassava Sciences	-$97.22M	-$2.32	N/A	12.69	N/A	N/A	-57.53%	-52.58%	5/6/2024 (Estimated)

Latest AVEO, SAVA, ADMP, and ONCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	ONCY Oncolytics Biotech	-$0.11	-$0.04	+$0.07	-$0.04	N/A	N/A
2/28/2024	Q4 2023	SAVA Cassava Sciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVEO AVEO Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
AVEO AVEO Pharmaceuticals	0.94	2.37	2.35
ONCY Oncolytics Biotech	N/A	9.01	9.01
SAVA Cassava Sciences	N/A	9.13	9.13

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
AVEO AVEO Pharmaceuticals	49.95%
ONCY Oncolytics Biotech	6.82%
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
AVEO AVEO Pharmaceuticals	3.29%
ONCY Oncolytics Biotech	0.10%
SAVA Cassava Sciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
AVEO AVEO Pharmaceuticals	114	34.76 million	33.62 million	Optionable
ONCY Oncolytics Biotech	29	75.42 million	75.35 million	Not Optionable
SAVA Cassava Sciences	29	43.25 million	39.35 million	Optionable

AVEO, SAVA, ADMP, and ONCY Headlines

Source	Headline
	Rail heralded as future for Thai logistics bangkokpost.com - April 17 at 1:27 PM
	Cassava Sciences (NASDAQ:SAVA) Trading 6.2% Higher marketbeat.com - April 16 at 3:43 PM
	Cassava Sciences (NASDAQ:SAVA) Sees Large Volume Increase marketbeat.com - April 15 at 2:49 PM
	Redemption Date Announced for Warrants globenewswire.com - April 15 at 9:20 AM
	Contrasting Cassava Sciences (NASDAQ:SAVA) & Nabriva Therapeutics (NASDAQ:NBRV) americanbankingnews.com - April 15 at 1:44 AM
	Nicklaus: Path to world food security goes through St. Louis stltoday.com - April 14 at 7:17 AM
	Cassava Sciences (NASDAQ:SAVA) Shares Down 9% americanbankingnews.com - April 14 at 4:42 AM
	Cassava Sciences (NASDAQ:SAVA) Trading Down 9% marketbeat.com - April 12 at 2:51 PM
	Vietnam has great potential for biofuel: experts vietnamnet.vn - April 12 at 2:00 PM
	Cassava Sciences Sees Unusually Large Options Volume (NASDAQ:SAVA) americanbankingnews.com - April 12 at 3:52 AM
	Investors Purchase Large Volume of Call Options on Cassava Sciences (NASDAQ:SAVA) marketbeat.com - April 11 at 4:50 PM
	Cassava Sciences (NASDAQ:SAVA) Sees Strong Trading Volume marketbeat.com - April 9 at 3:19 PM
	Fosukrom farmers trained on organic herbicides, pesticides modernghana.com - April 8 at 8:15 PM
	Zambians Feel the Personal Consequences of Climate Change—and Dream of a Sustainable Future insideclimatenews.org - April 8 at 8:15 PM
	Cassava Sciences (NASDAQ:SAVA) Trading Up 5.7% marketbeat.com - April 8 at 1:46 PM
	Gates Foundation’s agtech arm sets up shop in St. Louis to help smallholders in Africa agfundernews.com - April 5 at 2:17 AM
	5 Foods You Must Eat For A Longer, Healthier Life - Blue Zones Expert Reveals food.ndtv.com - April 5 at 1:13 AM
	Ag nonprofit launched by Gates Foundation opens HQ in Cortex, grows to 30 employees bizjournals.com - April 5 at 1:13 AM
	Strong quake rocks Taiwan, tsunami warnings issued msn.com - April 4 at 4:16 PM
	Can Africa one day help feed the world’s growing population? ft.com - April 3 at 3:22 AM
	Elevating knowledge about Africa in international business: KNUST’s Prof. Nathaniel Boso’s legacy myjoyonline.com - April 2 at 5:22 PM
	24 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava stockhouse.com - April 2 at 5:22 PM
	Tracing science’s transformative impact on manifesto implementation msn.com - April 2 at 10:59 AM
	FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the Firm accesswire.com - April 1 at 11:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamis Pharmaceuticals

NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

AVEO Pharmaceuticals

NASDAQ:AVEO

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Oncolytics Biotech

NASDAQ:ONCY

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Cassava Sciences

NASDAQ:SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial